Pathophysiology and management of diabetic gastroenteropathy by Meldgaard, Theresa et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Pathophysiology and management of diabetic gastroenteropathy
Meldgaard, Theresa; Keller, Jutta; Olesen, Anne Estrup; Olesen, Søren Schou; Krogh, Klaus;
Borre, Mette; Farmer, Adam; Brock, Birgitte; Brock, Christina; Drewes, Asbjørn Mohr
Published in:
Therapeutic Advances in Gastroenterology
DOI:
10.1177/1756284819852047
Publication date:
2019
Document license:
CC BY-NC
Citation for published version (APA):
Meldgaard, T., Keller, J., Olesen, A. E., Olesen, S. S., Krogh, K., Borre, M., ... Drewes, A. M. (2019).
Pathophysiology and management of diabetic gastroenteropathy. Therapeutic Advances in Gastroenterology,
12, 1-17. https://doi.org/10.1177/1756284819852047
Download date: 14. May. 2020
https://doi.org/10.1177/1756284819852047 
https://doi.org/10.1177/1756284819852047
Ther Adv Gastroenterol
2019, Vol. 12: 1–17
DOI: 10.1177/ 
1756284819852047
© The Author(s), 2019. 
Article reuse guidelines:  
sagepub.com/journals-
permissions
Therapeutic Advances in Gastroenterology
journals.sagepub.com/home/tag 1
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License  
(http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission 
provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction
The development of diabetic polyneuropathy can 
potentially alter neuronal structure and function 
anywhere in the peripheral, central and enteric 
nervous systems. Where small and large fibres 
(unmyelinated C and myelinated Aβ and Aδ fibres) 
in the somatic sensory nervous system are affected, 
the typical manifestation is a distal symmetrical 
polyneuropathy.1 Importantly, these symptoms 
can also be found in people with prediabetes.2 The 
somatic polyneuropathy is characterised by altera-
tions in the sensory system, and classically presents 
with marked changes in a number of sensations 
(including temperature and fine touch, balance, 
etc.) and can be painful or painless, although the 
former predominates.2 In community samples 
with diabetes, the prevalence of clinical symptoms 
is in the order of 30%, although this is likely to 
represent an underestimate as many people are not 
formally diagnosed.3
Although often overlooked, effects in the auto-
nomic nervous system most likely occur concur-
rently with those observed in the somatic nervous 
system. For example it is plausible that early dam-
age to small fibres, preceding large fibre neuropa-
thy, of the somatic nerves, which can be observed 
in skin biopsies4 also take place in other small fibres 
such as in the enteric nervous system. Autonomic 
neuropathy can be clinically silent and is often pre-
sent when polyneuropathy of the somatic nerves is 
present. The diagnosis is typically based on cardio-
vascular abnormalities. In particular, studies of 
RR-complexes in electrocardiograms have been 
used to describe heart rate variability, leading to 
the diagnosis of cardiac autonomic neuropathy. 
However, autonomic neuropathy also leads to gas-
trointestinal (GI) complications such as diabetic 
gastroenteropathy, which may affect the entire 
length of the GI tract. The underlying pathophysi-
ology, which is driven by a multitude of factors, 
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including microenvironmental factors such as 
hyperglycaemia, have a negative impact on the 
enteric motor and sensory functions and manifest 
as symptoms related to, e.g., motility and secretory 
dysfunctions.5–7 Hence, people with diabetic gas-
troenteropathy may experience a variety of bur-
densome symptoms, including dysphagia, 
dyspepsia, pain, bloating, diarrhoea, constipation 
and faecal incontinence, all of which adversely 
influences quality of life.
Although the focus of this review is diabetic gas-
troenteropathy, it should be emphasized that 
functional GI disorders are prevalent in the com-
munity. Hence, the presentation of diabetic gas-
troenteropathy and functional disorders such as 
functional dyspepsia and irritable bowel syn-
drome overlap and cannot be distinguished on 
the basis of symptoms or medical history (i.e. 
diabetes) alone. In fact, examinations of small 
bowel biopsies from patients with diabetes 
revealed neuropathy and myopathy only in a 
minority of patients.8 It is also clear that indi-
viduals with chronic disease have a higher preva-
lence of psychiatric disorders and are exposed to 
more stress than healthy subjects. These factors 
play an important role in the presentation and 
perceived severity of functional GI diseases.
The aims of this review are, however, to describe 
the pathophysiology of GI complications to dia-
betic neuropathy (gastroenteropathy) and to out-
line diagnostics and recent pharmacological and 
nonpharmacological treatment modalities for this 
burdensome condition.
Pathophysiology of diabetes-induced 
gastrointestinal complications
The term diabetic gastroenteropathy encom-
passes the cumulative impact that diabetes exerts 
on the GI tract. The pathophysiology is multifac-
torial and to date remains incompletely under-
stood. However, changes in the neuronal 
microenvironment are believed to be a major 
driver in the pathogenesis. Microvascular compli-
cations to diabetes lead to alterations of blood 
flow in the GI wall, and hence also to alterations 
in the microenvironment. Smooth muscle myo-
pathy is also thought to be a contributing factor to 
diabetic gastroenteropathy. However, smooth 
muscle myopathy may not be a primary distur-
bance, but is more likely a result of smooth mus-
cle cell atrophy induced through reduced trophic 
cues from interstitial cells of Cajal (which are also 
reduced in number).9 This link between reduced 
numbers of interstitial cells of Cajal and smooth 
muscle myopathy has been observed in animal 
models of diabetic gastroparesis and likely con-
tributes to abnormal motility.
The autonomic nervous system comprises (a) 
the sympathetic nervous system, (b) the para-
sympathetic nervous system (whose main neural 
substrate is the vagus nerve) and, according to 
the early and recently re-established definition, 
(c) the enteric nervous system.10,11 Alterations in 
either of these systems are involved in the under-
lying mechanism of burdensome GI complica-
tions in diabetes. As both the enteric nervous 
system and central nervous system (CNS) are 
involved in the bidirectional regulation and con-
trol of the GI homeostasis, any changes in either 
of these interconnected systems may result in 
altered GI function.
Changes at the level of the enteric nervous 
system
In diabetes, the microenvironment within the 
enteric nervous system is significantly altered due 
to the effect of e.g. long-term hyperglycaemia; oxi-
dative stress; inflammation; reduced levels of neuro 
transmitters, local hormones and nerve growth fac-
tors; and increased levels of fatty acids.12,13 
Recently, altered gut luminal microbiota has also 
been proposed to exert an influence. For example, 
lowered numbers of bacteria involved in produc-
tion of short chain fatty acids have been observed 
in diabetes. Short chain fatty acids have anti-
inflammatory effects in the GI wall and promote 
the secretion of the incretin hormone glucagon-
like peptide-1 (GLP-1). Lower levels of GLP-1 
influence glucose metabolism and can increase 
low-grade inflammation.14–18
Various components of the enteric nervous sys-
tem, (including enteric neurons, interstitial cells of 
Cajal, enteric glial cells) and smooth muscle cells 
are affected by the changes described above. 
Enteric neurons and interstitial cells of Cajal are 
particularly vulnerable to hyperglycaemia.19 When 
hyperglycaemic episodes are frequent, or when 
hyperglycaemia is persistent, shifts in the intracel-
lular glucose metabolism of neurons occur, conse-
quently leading to the formation of advanced 
glycation end-products, osmotic and oxidative 
stress as well as inflammation. Collectively, this 
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leads to cellular damage and ultimately to cell 
death, a process often referred to as glucose neu-
rotoxicity. These mechanisms are primarily 
described in the peripheral nervous system, but 
similar mechanisms are present in the enteric 
nervous system.20
The pathophysiological changes described above 
may lead to various degrees of diabetes-induced 
damage to enteric neurones. Preferential loss of 
large fibre neurons in the dorsal root ganglion 
and inhibitory motor neurons in the gut wall 
have been observed. In particular, selective loss 
of nitric oxide synthase and neuropeptide Y 
expressing inhibitory motor neurons has been 
shown in the human diabetic colon.21 This obvi-
ously has consequences for the contractile activ-
ity of the smooth muscle layers in the GI tract 
and hence the motility pattern. Furthermore, loss 
of interstitial cells of Cajal throughout the GI 
tract has been reported in both animal models 
and in humans,22,23 causing reduced frequency of 
spontaneous muscular contractions. In addition, 
decreased activity of gastric enteric glial cells has 
been observed in animal models of diabetes.24 
This may contribute to the development of gas-
troenteropathy in diabetes mainly because enteric 
glial cell functions such as neurotrophic support, 
immunosuppression and anti-inflammation is 
diminished with decreased activity.25,26
In contrast to the loss of motor neurons, it has 
recently been shown that levels of neurones con-
taining substance P and calcitonin gene-related 
peptide are increased in the stomach of porcine 
models of diabetes.27 Both these molecules are 
primarily involved in the afferent transmission of 
GI sensory and nociceptive information. Hence, 
such alterations may be related to the pathophys-
iological mechanisms of sensory symptom gen-
eration. Like in the somatic system, when sensory 
nerves are affected by enteropathy, pain from the 
gut can likely be spontaneous or evoked by exter-
nal or internal stimuli such as disturbances in 
motility and glandular functions. On the other 
hand, previous experimental studies where the 
gut was stimulated with electrical, mechanical 
and thermal stimuli, hypoalgesia to peripheral 
stimulation of both the upper and lower gut were 
shown, likely reflecting abnormal central pro-
cessing of the afferent activity.28 Moreover, rectal 
pain thresholds are correlated to cutaneous and 
autonomic dysfunction.29,30 The autonomic 
components of visceral hyperalgesia have only 
been investigated in detail in healthy subjects, 
but similar mechanisms are likely involved in 
diabetes.31
Changes at the level of the autonomic nervous 
system
Autonomic afferent and efferent signalling 
through the vagus nerve is directly involved in 
the extensive communication with the brain, 
forming the so-called gut-brain-axis. In both 
people with diabetes and in animal models, the 
number of neurons in the sympathetic and para-
sympathetic ganglions of the vagus nerve con-
nected to the GI tract is reduced32–34 as well as 
structural changes in the axons have been 
reported.35,36 In consequence, autonomic neu-
ropathy, influencing the vagus nerve, contributes 
to reduced GI function.
Changes at the level of the CNS
Although the blood–brain barrier offers some 
protection to the brain against hyperglycaemia, it 
has been observed that the microstructure in spe-
cific brain regions (diabetic encephalopathy) 
involved in visceral sensory processing is changed 
in diabetes.37
Manifestation of sensory symptoms from the 
abdomen, such as nausea, vomiting and pain, as 
well as unspecific fullness, shooting sensations, 
etc., may relate to abnormal function of the sen-
sory visceral nerves in combination with the 
encephalopathy (Figure 1).
We have previously shown that central reorgani-
sation of brain responses to visceral stimuli is 
associated to the burden of GI symptoms as well 
as heart rate variability as a proxy for diabetic 
autonomic neuropathy.38,39 This was supported 
by another study where visceral hyposensitivity 
was correlated to an increase in somatic referred 
pain areas, indicating central neuropathic-like 
changes.28 Although controversies exist regarding 
the pathogenesis of these changes, the findings in 
the CNS may be secondary to the peripheral neu-
ropathy, because the reduced afferent activity 
may cause adaptive shrinking.37,40 Finally, there is 
evidence from both neurophysiological and imag-
ing studies that descending pathways from the 
brainstem that normally ‘gates’ the incoming 
nociceptive barrage is malfunctioning in people 
with diabetes.30,41 Hence, as in somatic peripheral 
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neuropathy, abnormal central sensory processing 
and hyper-excitability may explain the visceral 
symptoms despite the peripheral hypoalgesia (as 
described above).42 Such neuroplastic mecha-
nisms were also seen e.g. in people with chronic 
pancreatitis, which is thought to have a strong 
neuropathic component, and this validated the 
findings.43
In summary, long-term diabetes induces marked 
structural and functional changes of the GI wall, 
parasympathetic, sympathetic and CNS altera-
tions. Especially, intrinsic and extrinsic neuronal 
communication of the GI tract is altered. Taken 
together, this leads to burdensome panenteric 
alteration of GI sensation and function, includ-
ing the biomechanics that drive GI motility.44,45
Diagnosis
As outlined above, diabetic gastroenteropathy 
can affect the entire GI tract, and consequently 
symptoms are not only very heterogeneous, they 
are also unspecific. The cardinal symptoms are 
nausea, vomiting, bloating and early satiety, how-
ever, symptoms range from dysphagia and heart-
burn to faecal incontinence. Thus, based on the 
patient reported symptoms, it is hardly possible to 
distinguish sequela of diabetes-associated GI dys-
function from organic diseases. This diagnostic 
dilemma is further aggravated by the fact that 
people with type 2 diabetes have an increased risk 
for a multitude of organic GI diseases, including 
reflux oesophagitis, gallstones and GI malignan-
cies.46 An increased cancer risk has also been 
observed in type 1 diabetes.47 Moreover, increased 
prevalence of other diseases with an autoimmune 
component affecting the GI tract such as coeliac 
disease48 are frequent and need to be taken into 
consideration.
Accordingly, it is important to first exclude 
organic disease using appropriate laboratory tests, 
endoscopy and imaging techniques in people pre-
senting with symptoms that could be attributed to 
diabetic gastroenteropathy (Figure 2). If these 
tests are unrevealing and symptoms do not 
respond to simple therapeutic measures (e.g. lax-
atives in chronic constipation), GI function tests 
can be used to diagnose disturbances associated 
with diabetic gastroenteropathy. Again, most 
clinically available function tests identify and 
quantify dysfunction of various GI segments and 
organs without being able to specifically prove the 
causation by or the relative importance of diabetic 
gastroenteropathy. For instance, severe oesopha-
geal hypomotility diagnosed by high resolution 
manometry can explain nonobstructive dysphagia 
in a person with diabetes, but could also be due to 
other aetiologies. Therefore, clinical plausibility 
and affection of other organ systems, e.g. cardiac 
autonomic neuropathy, should be taken into 
account. Impaired pancreatic polypeptide release 
has been suggested for specific diagnosis of gas-
troenteropathy,49 but measurements are not 
widely available. Likewise, antroduodenojenunal 
manometry with increased frequency of phase 
III-motility and hypomotility during phase II as 
well as postprandially is typical of autonomic neu-
ropathy, but available only at highly specialized 
centres and reserved for people with very severe 
symptoms.50
Figure 1. Neural pathways and mechanisms that 
may lead to pain and other sensory symptoms from 
the gastrointestinal system in people with diabetic 
neuropathy.
Neuropathic changes in the enteric nervous system where 
e.g., motility dysfunction can lead to sensory symptoms: 
(1) autonomic neuropathy influencing the parasympathetic 
(2) and (3) sympathetic pathways. Due to cross-talk 
between the nerve pathways and involvement of inhibitory 
pathways, this may indirectly modulate sensations from the 
gut; negative impact on visceral (4) (and somatic (5) if the 
peritoneum is involved) afferents lead to spontaneous and 
evoked pain. Structural and functional changes in the spinal 
cord (6) and brain (7) may lead to spontaneous and evoked 
pain, amplify afferent barrage and give abnormal referred 
pain to somatic structures (8). Spino-bulbo-spinal loops 
(9) that normally control pain intensity often malfunction in 
people with diabetes.
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Gastric emptying tests are recommended at an 
early stage in people with diabetes and dyspeptic 
symptoms. One reason for this is that gastric emp-
tying is of paramount importance for blood glu-
cose control.51 Another reason is that approximately 
20% of people with diabetes and disturbed gastric 
emptying have functional dumping syndrome, i.e. 
accelerated gastric emptying without prior upper 
GI surgery, in contrast to the more frequently 
reported complication gastroparesis. Both distur-
bances cannot be differentiated reliably based on 
symptoms, but obviously require different treat-
ment strategies.50,52 Recommendations regarding 
optimal use of gastric emptying tests are reviewed 
in detail elsewhere.50,53 Even in the absence of dys-
peptic symptoms, gastric emptying testing can play 
a role in exclusion of diabetic gastropathy as a 
cause of impaired blood glucose control not 
responding to antidiabetic medication.
Once settled on the diagnosis diabetic gastroenter-
opathy, treatment options are not overwhelming, 
but the cornerstone is tight glycaemic control.
New diagnostic modalities
The following modalities are selected because 
they are directly applicable in clinical practice 
Figure 2. Diagnostic algorithm in persons with suspected diabetic gastroenteropathy.
People with bothersome gastrointestinal symptoms should first undergo laboratory and imaging tests for exclusion of 
organic disease. If these are not helpful and symptoms are severe, or do not respond to simple therapeutic measures, 
GI function tests should be performed based on individual symptom pattern. These may reveal manifestations of 
diabetic gastroenteropathy (e.g. typical small bowel dysmotility in a person with diarrhoea), complications of diabetic 
gastroenteropathy (e.g. small bowel bacterial overgrowth) or differential diagnoses (e.g. lactose intolerance). BT: breath 
test; CHO: carbohydrate; EMG: Electromyography; GERD: gastro-oesophageal reflux disease; GI: gastrointestinal; HRM: high 
resolution manometry; SIBO: small bowel bacterial overgrowth; TG: triglyceride; WMC: wireless motility capsule.
Therapeutic Advances in Gastroenterology 12
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and therefore can be used to assess diabetic 
neuropathy.
13C-breath test. This test reflects the conversion 
of 13C isotope to 13C-CO by hepatic metabolism 
after absorption from the small intestine, thereby 
serving as a proxy for gastric emptying. This 
modality may not be as sophisticated as, for 
instance, magnetic resonance imaging or scintig-
raphy. However, this very accessible technique 
correlates well with scintigraphic data, can be 
used repeatedly in the same person, and may be a 
marked improvement in assessing gastric empty-
ing in clinical situations.
The wireless motility capsule. This system com-
promises an indigestible capsule that continuously 
measures pressure, temperature and pH as it 
passes through the GI tract.54 Although the modal-
ity has been available for some time, the optimal 
yield from this technology is still to be determined. 
The pH measurements are used mainly to estab-
lish the GI segment. However, with the growing 
evidence of the influence of gut microbiota on gas-
troenteropathy and metabolism in general, one 
could speculate that associations between the pH 
of the different segments and composition of the 
gut microbiome could be of interest. For example, 
more acidic caecal pH has been demonstrated in 
type 1 diabetes, which may represent increased 
caecal fermentation.55
3D-transit system. Finally, a number of emerging 
modalities are currently being developed for 
research use. The ambulatory Motilis 3D-transit 
system tracks electromagnetic capsules as they 
traverse the GI tract and measures changes in 
position, velocity of movements and orientation 
of the capsules. This reflects gut contractile activ-
ity and progression dynamics. Anatomical infor-
mation allows for detailed description of colonic 
motility, including regional transit times and 
motor patterns.56
Management
Management of blood glucose fluctuations
There is no cure for diabetic gastroenteropathy. 
Hence, the treatment aims are to delay progres-
sion, ease symptoms, manage complications and if 
possible restore function. The primary strategy to 
achieve this remains tight glycaemic control. 
Glycaemic management should be guided by age, 
disease duration and overall health and, if success-
ful, symptoms may improve. Dietary and lifestyle 
advice can provide persons with diabetes with tools 
for better long-term glycaemic control. In people 
with diabetes and gastroparesis, it can often be 
helpful to administer pre-prandial insulin after the 
meal or in reduced amount. Employment of an 
insulin pump may further contribute to tight gly-
caemic control in persons with insulin-dependent 
diabetes. Devices that allow for continuous glu-
cose monitoring in interstitial fluids in real time 
have become available and enable monitoring of 
time spent in target glucose range (‘time in range’) 
as well as warning trends toward hypoglycaemia or 
hyperglycaemia in real time.57 This modality has 
already proven its potential in modelling intestinal 
glucose absorption,58 and thus it can be expected 
to be a future important tool in validating glucose 
metabolism of the enteric system in physiological 
and pathophysiological setups. Continuous glu-
cose monitoring is recommended by national and 
international medical organisations and expert cli-
nician consensus guidelines, both in combination 
with pumps and in persons on multiple daily insu-
lin injections.57,59–61 As the number of hyper- and 
hypoglycaemic events are reduced, the concept is 
believed to have a neuroprotective effect. Besides 
optimisation of glycaemic control, no available 
treatments address the underlying polyneuropa-
thy. Hence available nonpharmacological and 
pharmacological treatment options targets symp-
toms of gastroenteropathy, the latter of which may 
be complicated by altered drug absorption in the 
diabetic gut.
Pharmacological management: absorption of 
medications
Widespread disease of the GI tract will have conse-
quences for the absorption of orally administered 
drugs.62 However, only few studies on small popula-
tions have addressed the effects of diabetes on net 
absorption of drugs.63 As diabetes-induced struc-
tural and functional alterations are observed 
throughout the GI tract, diabetic gastroenteropathy 
may alter drug absorption after oral administration.
Two important factors may be affected: (1) The 
release of drug substance from the controlled 
release formulations, which are designed to release 
drug with a predefined rate throughout the GI-tract. 
Changes in the intraluminal environment due to 
gastroenteropathy may alter drug release. (2) Drug 
absorption following oral administration, which is 
T Meldgaard, J Keller et al.
journals.sagepub.com/home/tag 7
possible throughout the GI-tract, with the upper 
small intestine as the main site for absorption.64 
Several changes of GI physiology and function 
related to diabetic gastroenteropathy may therefore 
influence drug absorption (Table 1). This can ulti-
mately result in therapeutic failure due to altered 
plasma levels.
One study in diabetes demonstrated that altera-
tions in gut transit time impacts mainly the phar-
macokinetics of drugs with poor intestinal 
absorption and controlled release formulations.63 
Further studies on disease–drug interactions are 
needed as the study on the influence of GI dys-
function on drug absorption from oral formula-
tions is still in its beginning.62,67
In conclusion, potential unpredictable drug 
absorption and the likelihood of treatment failure 
should be considered in people where diabetic 
gastroenteropathy may be present.68
Pharmacological management of motility 
dysfunction in the upper GI tract
Prokinetics. A number of prokinetic drugs have 
been studied for the management of motility dis-
turbances in the upper GI tract in people with 
diabetes, and have generally proven to be effec-
tive for symptom improvement in placebo-con-
trolled trials.69–72 Until now, no absolute 
association between symptom improvement and 
changes in upper GI motility before or after treat-
ment have been shown.70 This may be due to het-
erogeneity of study groups and use of sub-optimal 
methods for measuring gastric emptying time. 
Hence, two new metanalysis showed that there 
may in fact be an association between upper GI 
motility and symptoms when optimal methods 
are used.53,73 On the other hand it cannot be 
ruled out that central effects of prokinetics may 
explain the observed improvement of symptoms. 
The classical prokinetic drugs fall into two cate-
gories based on their primary molecular target. 
The D2-receptor antagonists metoclopramide 
and domperidone have been used to treat gastro-
paresis for many years and have proven effective 
for this indication in randomised placebo-con-
trolled trials.69 A multicentre study comparing 
the effectiveness of metoclopramide and dom-
peridone found the drugs to be equally effective 
against symptoms of gastroparesis, but with more 
adverse effects in the CNS reported in persons 
treated with metoclopramide.71 This finding can 
be explained by the ability of metoclopramide to 
cross the blood-brain barrier to a higher degree, 
thereby having an increased potential for mediat-
ing central adverse effects. In February 2009, the 
U.S. Food and Drug Administration (FDA) and 
European Medicines Agency appointed black 
box warnings for long-term use (more than 12 
weeks) of metoclopramide due to the risk of irre-
versible tardive dyskinesia, which has limited its 
use. The FDA has approved only metoclopramide 
for gastroparesis, although the risks for cardio-
vascular side effects seems to be higher than for 
domperidone.74 In Europe, domperidone is most 
often used, but caution should be taken due to 
risk of cardiac arrhythmias in the presence of 
prolonged QT-syndrome. Risk factors such as 
Table 1. Diabetic gastroenteropathy related factors that may influence drug absorption.55,64–66
GI factors influencing drug absorption Consequences
Dysmotility
(gastroparesis, functional dumping syndrome, 
diarrhoea and constipation inclusive)
Altered transit time and/or luminal water content
Small intestinal bacterial overgrowth Altered pH and transit time
Altered secretory function Reduced or increased luminal water content
Altered enteric microbiota Altered pH and luminal drug metabolism
Structural remodelling of the wall of the GI tract Altered intestinal transporters and gut wall 
metabolism
Reduced microvascular blood flow Altered absorption to systemic circulation
GI: Gastrointestinal.
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female sex, age above 65 years, electrolyte distur-
bances, polypharmacy, known heart disease, etc. 
should be taken into consideration when 
D2-receptor antagonists are used.75 Erythromy-
cin is a motilin and cholinergic receptor agonist 
that has also been used for decades to treat upper 
motility dysfunction in people with diabetes.70 
However, its clinical efficacy often diminishes 
after 2–4 weeks due to tachyphylaxis, and many 
patients experience adverse effect during long-
term use.70 A survey among people with gastro-
paresis observed a correlation between willingness 
to accept potentially lethal side effects and symp-
tom severity.76 This emphasizes how burdensome 
GI complications are.
The prokinetic action of erythromycin is likely a 
drug class effect, and other macrolides with less 
toxicity may be used, but evidence from controlled 
trials is not available. Novel molecular targets, 
including highly selective serotonin agonists, are 
currently under investigation for debilitating symp-
toms associated with diabetic gastroparesis, but 
have not yet been approved for this indication.72 
Prucalopride is currently available for other GI 
dysmotility disorders (see next section). It has a 
safe cardiovascular profile and may be used off-
label for treatment in selected cases.77 The syn-
thetic ghrelin analogue, relamorelin, with 
prokinetic properties, also appears to be safe and 
has shown promising results for the treatment of 
gastroparesis in phase IIA studies.78 Hence, relam-
orelin may be a potential drug to use in the future.
Tricyclic antidepressants. Low-dose nortripty-
line, amitriptyline, and desipramine can diminish 
symptoms in people with diabetes and chronic 
vomiting, who had an inadequate response to 
prokinetics.79 A multicentre trial has reported 
that amitriptyline relieve symptoms, although 
gastric emptying time was not lowered, in sub-
groups of patients with painful functional dyspep-
sia. This indicates a mechanism of action of 
tricyclic antidepressants on visceral hypersensitiv-
ity and not gastric emptying.80 However, in a large 
multicentre randomised controlled trial in adults 
with idiopathic gastroparesis, the use of nortripty-
line (up to 75 mg per day) compared with placebo 
for 15 weeks did not improve the overall symptom 
score.81 Thus, further research is warranted in 
order to make any conclusive recommendations.
Taken together, the serotonin and ghrelin recep-
tor agonists have generally been well tolerated 
and safe in humans without the cardiac or neuro-
logic adverse effects associated with ‘classic 
prokinetics’. Therefore, these agents (and poten-
tially tricyclic antidepressants) comprise promis-
ing therapeutics for future treatment of upper 
motility dysfunction in diabetes and other upper 
GI dysmotility disorders.
Pharmacological management of motility 
dysfunction in the lower GI tract
Natural bulking, osmotic and stimulant laxa-
tives. Lower GI symptoms in people with diabetes 
type 1 are associated with poor glycaemic control 
and quality of life.82 In randomised, placebo con-
trolled trials, the intake of the natural bulking psyl-
lium (10 g bid) or flaxseed (10 g bid) reduced 
symptoms of constipation and improved glycaemic 
control in people with type 2 diabetes.83,84
No studies have specifically investigated the effects 
of laxatives in persons with constipation as a com-
plication due to diabetic gastroenteropathy. It is 
commonly suggested, but not evidence based, to 
start with osmotic laxatives such as magnesia or 
polyethylene glycol. If this is insufficient, stimu-
lant laxatives such as bisacodyle, senna or picosul-
fate can be added. Lubiprostone, a chloride 
channel activator, increases secretion from the 
colon, thereby reducing colonic transit time and 
increasing the number of spontaneous bowel 
movements in persons with diabetes-related con-
stipation.85 Prucalopride, a 5-HT4 agonist, 
reduces transit time throughout the GI tract, and 
especially through the colon. Though not evalu-
ated in DM, the pharmacological profile of pruca-
lopride indicates that it is useful against 
constipation as part of the panenteric disorder 
often found in diabetes. Linaclotide, although reg-
istered for irritated bowel syndrome, may also be 
used in selected cases.86 Finally, the enzyme trans-
glucosidase (used as a dietary supplement) 
changes the gut microbiome and increases the 
weekly number of bowel movements in people 
with type 2 diabetes and constipation.87
Antibiotics, enzyme supplementation and dietary 
intervention. In addition, people with diabetes have 
an increased prevalence of diarrhoea as sequela to 
small intestinal bacterial overgrowth, bile acid diar-
rhoea, pancreatic insufficiency and coeliac disease. 
These should be treated specifically with antibiot-
ics, bile acid sequestrants, enzyme supplement or 
gluten-free diet whenever appropriate.
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Antidiarrhoeal products. Compared to the general 
population, people with diabetes have a two-fold 
risk of having diarrhoea (11 vs 6 %).88 Very often, 
diarrhoea is induced by glucose-stabilizing treat-
ment such as metformin or other medications 
commonly taken by people with diabetes. If no 
underlying condition is found for development of 
diarrhoea, pharmacological treatment will usually 
include dietary assessment and intervention in 
combination with loperamide, an opioid receptor 
agonist. Uncontrolled observational studies have 
shown that the α2 adrenergic agonist clonidine 
may reduce diarrhoea in people with diabetes. The 
use of clonidine is, however, restricted by its car-
diovascular side effects.89
Furthermore, diabetes significantly increases the 
risk of having faecal incontinence, which in fre-
quently is aggravated by diarrhoea. If an underly-
ing cause of diarrhoea can be identified, it must be 
addressed. If not, loperamide or dietary interven-
tion may be indicated. In a number of persons, fae-
cal incontinence is associated with neuropathy and 
reduced sensibility of the anal canal. In these cases, 
loperamide, suppositories or enemas should be 
considered. Treatment of refractory cases is very 
complex and may even require a stoma.
Neuromodulation. Neuromodulatory electrical 
stimulation of the sacral nerve, which is described 
in detail later, is an emerging technique for the 
treatment of faecal incontinence and potentially 
sensitivity in the anal canal.90 However, the role 
of sacral nerve stimulation in people with dia-
betic gastroenteropathy has not been investi-
gated specifically.
Pharmacological management of sensory 
symptoms
In the management of abdominal pain in diabetes 
it is often impossible to distinguish between the 
different organ manifestations. This is due to the 
vague presentation of visceral symptoms with 
changing presentation of the pain and referral to 
somatic structures, and this should be taken into 
consideration.91 It can also be difficult to distin-
guish between symptoms such as nausea and pain 
evoked by dysmotility and those that are related to 
the sensory (and central) neuropathy per se. In such 
cases the primary reason for pain such as constipa-
tion should be treated primarily. If all such reasons 
for the pain can be excluded, management should 
be directed against the neuropathy. Although only 
few studies have addressed treatment of visceral 
sensory symptoms in people with diabetes, the 
pharmaceutical options most often applied are 
reviewed here. On the other hand, the individual 
variability in phenotypical presentation of pain in 
diseases is greater between people than between 
pain syndromes. This indicates that mechanistic 
aetiologies and subsequent successful treatment 
should be based at the level of the individual rather 
than the disease per se.92 Hence, the recommenda-
tion for pharmacological management of visceral 
neuropathic pain follows the guidelines used for 
somatic neuropathies.93
Tricyclic antidepressants. As stated above tricy-
clic antidepressive medications can be used to 
manage symptoms in gastroparesis, likely because 
many of the clinical presentations are conse-
quences to sensory neuropathy. A detailed 
description is outside the scope of this paper, but 
for disorders with peripheral and central neurop-
athy, these adjuvant analgesics are often used.
Selective serotonin-noradrenaline reuptake inhibi-
tors and gabapentinoids. Depending on the clini-
cal situation, other pharmacological compounds 
for the use of treating diabetes induced somatic 
and neuropathic pain also include selective sero-
tonin-noradrenaline reuptake inhibitors as well as 
the gabapentinoids (gabapentin and pregabalin), 
and the drugs can be used in combination.
Opioids. In difficult and severe cases, more potent 
analgesics such as opioids may be needed, but, if 
possible, long-term treatment should be avoided 
due to adverse effects, e.g. high risk of masking 
hypoglycaemic events.94,95 Although most drugs 
have a certain potency, all have GI (or CNS) side 
effects and safety is often the major limitation in 
pain management, especially for opioids.75,96 
Hence, the balance between effect and side-effects 
is more relevant than the potency of the analge-
sics. This balance is however highly individual, 
and as no valid predictors for individualised treat-
ment is available, a period with ‘trial and error’ is 
often necessary. There should also be awareness 
on opioid-induced bowel dysfunction that by 
itself may lead to gastroparesis and constipation 
and lead to a vicious circle that can intensify the 
pain.97,98
Modern pain management. There is always more 
to analgesia than analgesics, and pharmacological 
management can seldom stand alone. Therefore, 
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modern pain management of diabetic gastroen-
teropathy also includes e.g., invasive procedures, 
supportive care and nursing (multimodal analge-
sia). Finally, it should not be forgotten that indi-
vidual experiences and manifestations of pain are 
influenced by complex interactions between sen-
sory, pathophysiological, affective, socio-cultural, 
behavioural and cognitive elements. An active 
screening for psychiatric comorbidity, including 
anxiety and depression, should be done as up to 
40% of chronic pain patients are depressed, and 
identification of mood disorders may select per-
sons where adjuvant therapy with antidepressants 
are particular beneficial.99 It should be stressed 
that treatment of abdominal pain secondary to 
diabetic gastroenteropathy is complex and 
involves a multidisciplinary approach including 
diabetologists, gastroenterologists, pain special-
ists, dietitians and psychologists.
Dietary management
People with diabetic gastroenteropathy are at risk 
of developing dehydration and poor nutritional 
status.100 Most studies on dietary treatment in 
diabetes have included people with gastroparesis 
who may have insufficient dietary intake due to 
early satiety, postprandial fullness, nausea and 
vomiting. However, the literature regarding the 
evidence for the nutritional intervention is scarce. 
Among people with gastroparesis, 64% had insuf-
ficient daily intake of energy, vitamins and miner-
als.100 In contrast, another study demonstrated 
that people with diabetes were capable of main-
taining a sufficient daily caloric intake.101 The 
normal dietetic recommendation for diabetics 
includes a high-fibre content, which is not appro-
priate for people with gastroparesis. A small par-
ticle diet cause less upper GI symptoms than a 
conventional diet and represents food items that 
are easily processed into small particle size (maxi-
mum 2 mm in diameter). In a study by Olausson 
et al., the fibre and fat content of the diet was nor-
mal, but it excluded husks/peels (e.g. corn), 
membranes (e.g. orange), stringy foods (e.g. rhu-
barb), seeds and grains (e.g. whole grain), and 
poorly digestible particles (e.g. salad).102
It has been observed that gastric emptying is sig-
nificantly delayed in healthy volunteers after a 
high-fat meal compared with a low-fat meal.103 
However, the majority of well-controlled studies 
indicate that gastric emptying upon high-fat meals 
is similar to other nutrient compositions matched 
for calorie and volume.104 One explanation may be 
that high-fat meals increase visceral sensitivity. 
This may explain, why correspondingly, a high-fat 
solid meal causes more symptoms than a low-fat 
liquid meal in people with diabetic or idiopathic 
gastroparesis.105,106 Also, high-fat liquid meals 
were better tolerated than high-fat solid meals.107 
High-osmolality liquids with more than 350 
mOsm.kg delay gastric emptying in healthy per-
sons108 but the effect in people with diabetes is 
unknown.
Since fat, fibre, meal-size and consistency of 
foods all seem to influence gastric emptying and 
symptoms, the dietetic intervention in people 
with diabetes and gastroparesis should include 
several small meals (five to six) with a small parti-
cle size, a moderate-to-low content of fat and 
fibre, and a high content of liquids both in and 
alongside the meal. In case of weight loss, high-fat 
liquid meals might be an option. Oral intake is 
preferred, but in people with severe symptoms 
and weight loss, enteral (particular jejunal) or 
parenteral nutrition can be indicated.109
Neuromodulatory treatment
Although not neuromodulatory per se, a novel 
nonpharmacological vibrating capsule is assumed 
to induce a normal peristaltic wave in the large 
intestine to alleviate constipation. Although it 
has been shown to improve transit times in some 
people with functional constipation by a convey-
ing by vibration approach,110 further evidence is 
needed.
Electrical stimulation of the GI tract was first used 
over 50 years ago to improve motility in postoper-
ative ileus.111 Subsequent studies demonstrated 
that gastric electrical stimulation could improve 
gastric emptying and gastric dysrhythmias,112 both 
important pathophysiological features of gastropa-
resis.113 Gastric electrical stimulation is currently 
used for the treatment of people with gastroparesis 
whose symptoms are refractory to medical inter-
ventions, particularly in the context of weight loss, 
however, it has not affected the transit time. The 
method is invasive and involves laparoscopic sur-
gical placement of electrodes on the externa mus-
cular wall of the gastric antrum (Figure 3a). These 
electrodes are then subsequently attached to a 
programmable signal generator box, which is 
implanted in a subcutaneous pouch in the left 
flank. The complication rates are in the order of 
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10%, the most common being subcutaneous 
pocket infection.114 The mechanism of action of 
gastric electrical stimulation is incompletely 
understood, but it is thought that it may either 
modulate vagus nerve function to improve gastric 
accommodation or influences vagal afferent sig-
nalling to the CNS. Outcome and efficacy data on 
gastroparesis in people with diabetes are largely 
derived from open-label single-centre studies in 
highly selected persons. Meta-analytic evidence, 
however, suggests that gastric electrical stimula-
tion improves the cardinal symptoms of gastropa-
resis, such as nausea and vomiting, improves 
generic quality of life and reduces the need for 
enteral or parenteral nutritional support.115
It has been shown that acute hyperglycaemia 
inhibits anal sphincter function, leading to a reduc-
tion in rectal compliance, which can lead to faecal 
incontinence.116 Although the mainstay of man-
agement remains medical, a number of neuromod-
ulatory therapies are emerging, such as sacral nerve 
stimulation or percutaneous tibial nerve stimula-
tion. Typically, a test or trial stimulation period is 
undertaken where the signal generator is external, 
and, if successful, this can be internalised in a sub-
cutaneous pouch (Figure 3b). The majority of the 
studies to date have used cross-over designs, which 
have demonstrated a degree of efficacy in reducing 
the number of episodes of faecal incontinence, 
although these have not been specifically designed 
for people with diabetes.117 Albeit not tested in dia-
betes, percutaneous tibial nerve stimulation is a 
novel ambulatory therapy for faecal incontinence 
(Figure 3c). However, a large multi-centre ran-
domised controlled trial comparing 12 weeks of 
percutaneous tibial nerve stimulation with sham 
stimulation did not demonstrate any benefit over 
12 weeks of treatment.118
Non-invasive electrical stimulation is a promising 
novel approach for the treatment of abdominal 
symptoms that appears to increase gastric empty-
ing and colon transit time. If proven, this would 
constitute a very applicable treatment approach.119 
Conclusion
The understanding of diabetic neuropathy has 
improved rapidly over the last decade. Increased 
understanding of the different symptoms, and 
how they interact with motor and secretory func-
tions of the gut may be a major breakthrough the 
treatment of the, often very diffuse, symptoms 
and complaints that have a major impact on 
quality of life. The management of diabetic gas-
troenteropathy is still difficult and should involve 
a multidisciplinary team including pharmacolo-
gists, nurses, dieticians, diabetologists, gastroen-
terologists and surgeons as well as health 
professionals from other specialities. On the 
other hand, new techniques to unravel the gut 
function as well as better treatment modalities 
are emerging. Together with increased awareness 
on the symptoms and better glycaemic control, 
diabetic gastroenteropathy and its different man-
ifestations will undoubtedly be less burdensome 
in the near future.
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